Phaseline

Companies › Resilient Pharmaceuticals

Resilient Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 20 registered trials: 12 Phase 2, 6 Phase 1, 2 Phase 3; Neurology, Oncology, Other, Psychiatry; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Midomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 1Healthy Volunteers; Post-Traumatic Stress Disorder; PTSD, Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder …Feb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05783817MidomafetaminePhase 2Obsessive-Compulsive DisorderPsychiatryDec 2026
NCT07584720MidomafetaminePhase 1Healthy VolunteersOtherFeb 2027
NCT05770375MidomafetaminePhase 1SchizophreniaPsychiatryMar 2027
NCT05770375MidomafetaminePhase 1SchizophreniaPsychiatryMar 2027
NCT05770375MidomafetaminePhase 1SchizophreniaPsychiatryMar 2027
NCT07494214MidomafetaminePhase 1HealhtyOtherMar 2027
NCT06117306MidomafetaminePhase 3Post-Traumatic Stress DisorderPsychiatryMar 2027
NCT07569159MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryApr 2027
NCT05219175MidomafetaminePhase 2Stress Disorders, Post-TraumaticPsychiatryApr 2027
NCT05837845MidomafetaminePhase 2PTSDPsychiatryMay 2027
NCT05732155MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryJun 2027
NCT06683014MidomafetaminePhase 2Borderline Personality DisorderPsychiatryJun 2027
NCT07301632MidomafetaminePhase 2Chronic Neuropathic PainNeurologyDec 2027
NCT06394284MidomafetaminePhase 3PTSD, Post Traumatic Stress DisorderPsychiatryDec 2027
NCT05790239MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryMar 2028
NCT06989957MidomafetaminePhase 1Posttraumatic Stress DisorderPsychiatryAug 2028
NCT05584826MidomafetaminePhase 2CancerOncologyNov 2028
NCT06418178MidomafetaminePhase 2Posttraumatic Stress DisorderPsychiatryOct 2029
NCT07288151MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryJan 2030
NCT07118839MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryMay 2030

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

SLC6A3 (1) SLC6A4 (1) SLC6A2 (1)

Companies with the same targets

Axsome Therapeutics Otsuka Remedy Definium Therapeutics US Currax Pharmaceuticals AlgoTherapeutix CSPC ZhongQi Pharmaceutical Technology Primus Pharmaceuticals Gradalis Intra-Cellular Therapies

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.